Skip to content

Oruka Therapeutics, Inc. ORKA Cash Flow Statement

TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
-$116.25M+25.3%-$105.43M+25.6%-$159.57M-170%-$157.92M-396%-$155.59M-1,306%
$110K+93.0%$83K+88.6%$82K+310%$73K+462%$57K+307%
$26.33M-13.2%$24.24M-5.1%$35.04M+226%$34.65M+2,918%$30.34M+5,251%
-$90.92M+29.5%-$88.21M+18.5%-$123.45M-140%-$140.87M-900%-$128.93M-3,494%
$269K$209K$335K$407K
-$154.05M+46.4%-$96.75M+70.7%-$404.85M-$282.57M-$287.43M
-$34.05M-107%-$14.64M-103%$91.25M-78.4%$476.27M+4,282%$509.57M+10,401%
-$91.19M-$88.42M-$123.79M-$141.28M

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Oruka Therapeutics, Inc. generate?
Oruka Therapeutics, Inc. (ORKA) generated -$90.9M in operating cash flow over the trailing twelve months.
What is Oruka Therapeutics, Inc.'s free cash flow?
After $269.0K of capital expenditures, Oruka Therapeutics, Inc.'s free cash flow was -$91.2M over the trailing twelve months, up 23.6% year over year.
Where does Oruka Therapeutics, Inc.'s cash flow data come from?
Every line is extracted from Oruka Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.